Two new companies have received substantial funding to pursue neo-antigens for cancer immunotherapy: Gritstone Oncology raised $102MM to pursue lung cancer and Neon Therapeutics raised $55MM to develop neoantigen-based therapeutic vaccines and T cell therapies to treat cancer. Continue reading
![](https://blogs.shu.edu/cancer/files/2014/07/cancerBiology180x110.jpg)